BACKGROUND: The relationship between psychiatric consultation and antipsychotic prescribing in nursing homes (NH) is unknown. OBJECTIVE: To identify the association between psychiatric consultant groups and NH-level antipsychotic prescribing after adjustment for resident case-mix and facility characteristics. RESEARCH DESIGN AND SUBJECTS: Nested cross-sectional study of 60 NHs in a cluster randomized trial. We linked facility leadership surveys to October 2009-September 2010 Minimum Data Set, Nursing Home Compare, the US Census, and pharmacy dispensing data. MEASURES: The main exposure is the psychiatric consultant group and the main outcome is NH-level prevalence of atypical antipsychotic use. We calculated annual means and interquartile ranges of NH-level antipsychotic use for each consultant group and arrayed consultant groups from lowest to highest prevalence. Generalized linear models were used to predict antipsychotic prescribing adjusting for resident case-mix and facility characteristics. Observed versus predicted antipsychotic prescribing levels were compared for each consultant group. RESULTS: Seven psychiatric consultant groups served a range of 3-27 study facilities. Overall mean facility-level antipsychotic prescribing was 19.2%. Mean prevalence of antipsychotic prescribing ranged from 12.2% (SD, 5.8) in the lowest consultant group to 26.4% (SD, 3.6) in the highest group. All facilities served by the highest-ranked consultant group had observed antipsychotic levels exceeding the overall study mean with half exceeding predictions for on-label indications, whereas most facilities served by the lowest-ranked consultant group had observed levels below the overall study and predicted means. CONCLUSIONS: Preliminary evidence suggests that psychiatric consultant groups affect NH antipsychotic prescribing independent of resident case-mix and facility characteristics.
BACKGROUND: The relationship between psychiatric consultation and antipsychotic prescribing in nursing homes (NH) is unknown. OBJECTIVE: To identify the association between psychiatric consultant groups and NH-level antipsychotic prescribing after adjustment for resident case-mix and facility characteristics. RESEARCH DESIGN AND SUBJECTS: Nested cross-sectional study of 60 NHs in a cluster randomized trial. We linked facility leadership surveys to October 2009-September 2010 Minimum Data Set, Nursing Home Compare, the US Census, and pharmacy dispensing data. MEASURES: The main exposure is the psychiatric consultant group and the main outcome is NH-level prevalence of atypical antipsychotic use. We calculated annual means and interquartile ranges of NH-level antipsychotic use for each consultant group and arrayed consultant groups from lowest to highest prevalence. Generalized linear models were used to predict antipsychotic prescribing adjusting for resident case-mix and facility characteristics. Observed versus predicted antipsychotic prescribing levels were compared for each consultant group. RESULTS: Seven psychiatric consultant groups served a range of 3-27 study facilities. Overall mean facility-level antipsychotic prescribing was 19.2%. Mean prevalence of antipsychotic prescribing ranged from 12.2% (SD, 5.8) in the lowest consultant group to 26.4% (SD, 3.6) in the highest group. All facilities served by the highest-ranked consultant group had observed antipsychotic levels exceeding the overall study mean with half exceeding predictions for on-label indications, whereas most facilities served by the lowest-ranked consultant group had observed levels below the overall study and predicted means. CONCLUSIONS: Preliminary evidence suggests that psychiatric consultant groups affect NH antipsychotic prescribing independent of resident case-mix and facility characteristics.
Authors: Joel E Streim; Elizabeth W Beckwith; Demetra Arapakos; Patricia Banta; Renee Dunn; Thomas Hoyer Journal: Psychiatr Serv Date: 2002-11 Impact factor: 3.084
Authors: Joanne Fenton; Allen Raskin; Ann L Gruber-Baldini; A Srikumar Menon; Sheryl Zimmerman; Bruce Kaup; David Loreck; Paul E Ruskin; Jay Magaziner Journal: Am J Geriatr Psychiatry Date: 2004 May-Jun Impact factor: 4.105
Authors: Camilla B Pimentel; Jennifer L Donovan; Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Abir O Kanaan; Celeste A Lemay; Kathleen M Mazor; Jennifer Tjia; Becky A Briesacher Journal: J Am Geriatr Soc Date: 2015-02 Impact factor: 5.562
Authors: Noah M Ivers; Monica Taljaard; Vasily Giannakeas; Catherine Reis; Cara L Mulhall; Jonathan M C Lam; Ann N Burchell; Gerald Lebovic; Susan E Bronskill Journal: Implement Sci Commun Date: 2020-02-25
Authors: Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn Journal: Psychopharmacology (Berl) Date: 2016-06-01 Impact factor: 4.530
Authors: Sebastian Rios; Christopher M Perlman; Andrew Costa; George Heckman; John P Hirdes; Lori Mitchell Journal: BMC Geriatr Date: 2017-10-23 Impact factor: 3.921
Authors: L Desveaux; M Saragosa; J Rogers; L Bevan; H Loshak; A Moser; S Feldman; L Regier; L Jeffs; N M Ivers Journal: Implement Sci Date: 2017-05-26 Impact factor: 7.327
Authors: Natali Jokanovic; Kris M Jamsen; Edwin C K Tan; Michael J Dooley; Carl M Kirkpatrick; J Simon Bell Journal: Drugs Real World Outcomes Date: 2017-12